Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi

Tropical Medicine and International Health

Volumn 2, Issue 5, 1997, Pages 482-487

  Zuñiga, Claudio ^a   Palau, Teresa ^b   Penin, Pilar ^c   Gamallo, Carlos ^d   De Diego, Jose Antonio ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Chagas' disease; Protective effect; T. cruzi; Trypanosoma rangeli; Vaccine

Indexed keywords

PROTOZOAL PROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; INFLAMMATORY INFILTRATE; MALE; MORTALITY; MOUSE; NONHUMAN; PARASITE VIRULENCE; PARASITEMIA; PROTECTION; PSEUDOCYST; STRAIN DIFFERENCE; TRYPANOSOMA; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 0030925722     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.1997.tb00171.x     Document Type: Article

References (14)

1. Almeida IC, Milani SR, Gorin PA & Travassos LR (1991) Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies, Journal of Immunology 146, 2394-400.
2. Anthony R, Johnson C & Soussa O (1979) Use of Micro-Elisa for quantitating antibody to Trypansoma cruzi and Trypanosoma rangeli. American Journal of Tropical Medicine and Hygiene 6, 969-973.
3. Arias AR & Ferro E (1988) Quantification of Trypanosoma cruzi parasitaemia by direct micromethod. Transactions of the Royal Society of Tropical Medicine and Hygiene 82, 248.
4. Avila JL & Rojas M (1990) Elevated cerebroside antibody levels in human visceral and cutaneous leishmaniasis, Trypanosoma rangeli infection, and chronic Chagas' disease. American Journal of Tropical Medicine and Hygiene 43, 89-306.
5. Basso B, Moretti E, Fontenia S & Vottero-Cima (1989) Trypanosoma (Schizotrypanum) cruzi and Trypanosoma (Herpetosoma) rangeli. II Overlapping of antigenic spectrum. Revista Latinoamericana Microbiologica 2, 141-146.
6. Campbell D, Gonzalez C, Jaramillo C, Montilla M, Rojas W, Labrada L et al. (1993) Resúmen det taller sobre el uso de la reactión en cadena de la polimerasa (PCR) para distinguir entre Trypanosoma cruzi y Trypanosoma rangeli. Biomédica (Columbia) 2, 94-101.
7. Freitas JLP, Lion MF & Tartari JTA (1953) Resultados de uma investigação sobre moléstia de Chagas realizada no municipio de Maråflia e outros, com estudo clinico de dois casos agudos da doença. Rev. Hosp. Cl. São Paulo 8, 81-92.
8. Guhl F, Hudson L, Marinkelle C, Morgan S & Jaramillo C (1985) Antibody response to experimental Trypanosoma rangeli infection and its implications for immunodiagnosis of South American trypanosomiasis. Acta Tropica 42, 311-318.
9. Lima MT, Jansen AM, Rondinelli E & Gattass (1991) Trypanosoma cruzi: properties of a clone isolated from CL strain. Parasitology Research 77, 77-81.
10. Mansfield JM (1977) Non pathogenic trypanosomes of mammals. In: Parasitic protozoa (ed JP Kreier). Academic Press, New York, 297-317.
11. Marsden PD (1967) Trypanosoma cruzi infection on CFI mice. I. Mortality with different doses of trypanosomes. American Tropical Medicine and Parasitology 61, 57-61.
12. Schottelius J (1987) Neuraminidase fluorescence test for the differentiation of Trypanosoma cruzi and Trypanosoma rangeli. Tropical Medicine Parasitology 38, 323-327.
13. Urdaneta-Morales S &. Tejero F (1985) Trypanosoma (Herpetosoma) rangeli Tejera 1920: Mouse model for high sustained parasitaemia. Journal of Parasitology 4, 409-414.
14. WHO (1985) Chagas' disease in the region of the Americas. Current status. Weekly Epidemiological Record 60, 37-42.